Li Jing-Ting, Liao Zhang-Xiu, Ping Jie, Xu Dan, Wang Hui
Department of Pharmacology, Basic Medical School of Wuhan University, Luojia Hill, Wuhan 430071, China.
J Gastroenterol. 2008;43(6):419-28. doi: 10.1007/s00535-008-2180-y. Epub 2008 Jul 4.
Activation of hepatic stellate cells (HSCs) is the dominant event in liver fibrosis. The early events in the organization of HSC activation have been termed initiation. Initiation encompasses rapid changes in gene expression and phenotype that render the cells responsive to cytokines and other local stimuli. Cellular responses following initiation are termed perpetuation, which encompasses those cellular events that amplify the activated phenotype through enhanced growth factor expression and responsiveness. Multiple cells and cytokines play a part in the regulation of HSC activation. HSC activation consists of discrete phenotype responses, mainly proliferation, contractility, fibrogenesis, matrix degradation, chemotaxis and retinoid loss. Currently, antifibrotic therapeutic strategies include inhibition of HSC proliferation or stimulation of HSC apoptosis, downregulation of collagen production or promotion of its degradation, administration of cytokines, and infusion of mesenchymal stem cells. In this review, we summarize the latest advances in our understanding of the mechanisms of HSC activation and possible antifibrotic therapeutic strategies.
肝星状细胞(HSCs)的激活是肝纤维化中的主要事件。HSC激活过程中的早期事件被称为起始。起始包括基因表达和表型的快速变化,使细胞对细胞因子和其他局部刺激产生反应。起始后的细胞反应被称为维持,其中包括那些通过增强生长因子表达和反应性来放大激活表型的细胞事件。多种细胞和细胞因子参与了HSC激活的调节。HSC激活包括离散的表型反应,主要是增殖、收缩性、纤维化形成、基质降解、趋化性和视黄醇丧失。目前,抗纤维化治疗策略包括抑制HSC增殖或刺激HSC凋亡、下调胶原蛋白产生或促进其降解、给予细胞因子以及输注间充质干细胞。在本综述中,我们总结了对HSC激活机制和可能的抗纤维化治疗策略理解的最新进展。